莫西沙星治疗慢性支气管炎急性加重的临床疗效及体外抗菌活性的研究

Study on efficacy of moxifloxacin in the treatment of AECB and its antimicrobial activity in vitro

目的评价莫西沙星口服胶囊治疗慢性支气管炎急性加重(AECB)的临床疗效及体外抗菌活性。方法采用随机、开放、平行对照试验设计。选择AECB病例100例,其中可评价病例86例,莫西沙星治疗组(试验组)42例,给莫西沙星400 mg qd,疗程5-10 d;左氧氟沙星治疗组(对照组)44例,给左氧氟沙星200 mg,hid,疗程7-14 d。结果莫西沙星治疗组与左氧氟沙星治疗组临床有效率分别为92.86%(39/42)和88.64%(39/44);痊愈率分别为78.57%(33/42)和68.18%(30/44)。两组有效率、痊愈率经统计学处理,无显著差异(P>0.05);细菌清除率分别为96.88%(31/32)和82.14%(23/28),细菌阴转率分别为96.88%(31/32)和82.14%(23/28),两组细菌清除率、阴转率无显著差异(P>0.05)。结论莫西沙星治疗AECB临床疗效可靠。

OBJECTIVE: To evaluate the efficacy in treating AECB with oral moxifloxacin and the antimicrobiol activity in vitro. METHODS: The trial design was random, open, and parallel control. 100 patients with AECB were involved. 86 Cases evaluated were randomly divided into the test group or the control group. 42 Patients in test group were given 400 mg moxifloxacin capsule for 5-10 d, while 44 patients in control group were given 200 mg levofloxacin capsule twice a day for 7-14 d. RESULTS: The effective rates of moxifloxacin and levofloxacin were 92.86% (39/42) and 88.64% (39/44); the recovery rates were 78.57% (33/42) and 68.18% (30/44, respectively. The bacterial eradication rates were 96.88% (31/32) and 82.14% (23/28) in two groups. There was no significant difference between the two groups (P > 0.05). CONCLUSION: Moxifloxacin has good effect against AECB.